Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona

On November 20, 2026 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, reported updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051, an investigational, oral, selective WEE1 inhibitor. Interim results will be presented today in a Plenary Oral Session at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, by Timothy A. Yap, MBBS, PhD, FRCP, of The University of Texas MD Anderson Cancer Center, the lead investigator of the study. As of the November 1, 2026 cut off date, 56 patients had received APR-1051 across all dose levels. The interim dataset includes one confirmed (on treatment for more than 10 months at cutoff) and one unconfirmed RECIST 1.1 partial response in patients with PPP2R1A-mutated uterine cancers and five patients with stable disease lasting more than four months. Pharmacodynamic evidence of WEE1 target engagement across multiple dose levels, together with the safety profile and longer follow-up on previously reported clinical activity, support continued dose optimization and continuous once-daily administration. Aprea plans to enroll at least 50 patients with uterine serous carcinoma (USC) or cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC), as dose escalation and backfill expansion enrollment continue, with completion of dose escalation and backfill expansion enrollment expected in the second quarter of 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Updated ACESOT-1051 findings

The presentation, "Interim Results From the First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051)," includes the following findings:

· Clinical activity and durability: Out of the 56 patients who enrolled in this dose escalation trial (including those patients treated at doses believed to be subtherapeutic), 43 are evaluable for response. Two patients with PPP2R1A-mutated uterine cancers achieved RECIST 1.1 partial responses, one confirmed and one unconfirmed. The confirmed response, in a patient with uterine carcinosarcoma treated at 220 mg, was ongoing with treatment beyond 10 months at the time of data cutoff. Sixteen patients had a best overall response of stable disease, five of which had a duration of 4 months or longer. Thirteen patients were still awaiting their initial on-treatment imaging studies at the time of data cutoff.

· WEE1 target engagement: Pharmacodynamic data (PD) from paired skin punch biopsies were stained by IHC for phosphorylation of CDK1-Y15, an established PD marker of WEE1 target engagement. Reductions of at least 50% in pCDK1-Y15 from baseline were observed in 21 of 25 evaluable patients (84%) across multiple dose levels.

· Initial Safety and tolerability: One dose-limiting toxicity (DLT) was observed among 56 treated patients. The DLT was elevation of AST and ALT without elevation in bilirubin in blood tests in a patient with known liver metastases treated at the 50 mg dose level. Grade 3/4 neutrophil count decrease was reported in 4 patients (7%) (1 Grade 3, 3 Grade 4, one of which was serious) all at the 300 mg dose level, with no reported cases of febrile neutropenia. Two patients (4%) experienced Grade 3 pneumonitis, both reported as serious. Other Grade ≥3 treatment-related adverse events included fatigue (5%), lymphocyte count decrease (4%), dyspnea (2%) and diarrhea (2%). The most common all grade treatment-related adverse events were nausea (41%), fatigue (25%), diarrhea (14%) and vomiting (14%).

· Pharmacokinetics: APR-1051 exposure increased with once-daily dosing through 300 mg, with an approximately 18-hour median half-life supporting once-daily dosing. Dose escalation has been modified to include 250 mg and 350 mg dose levels, and Part 1 now provides for up to 110 patients; previously disclosed dose levels of 400 mg and 500 mg are under evaluation.

"These interim results reinforce our focus on advancing APR-1051 in biomarker selected cancers," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "The ongoing confirmed partial response, additional unconfirmed partial response, and prolonged stable disease observed in multiple heavily pre-treated patients provide encouraging early evidence of single-agent clinical activity, supported by WEE1 target engagement and pharmacokinetics compatible with continuous once-daily dosing. Our strategy is to transition from a broad, biomarker-enriched Phase 1 study toward more focused expansion cohorts in patient populations most likely to benefit from APR-1051. Our goal is to evaluate whether APR-1051 can produce clinically meaningful and durable responses in a well-defined patient population with significant unmet medical need."

Expanded enrollment focused on biologically selected cancers

Aprea is refining enrollment to evaluate APR-1051 in populations that may be particularly sensitive to WEE1 inhibition. The Company is working with a diagnostics partner to develop an immunohistochemistry (IHC) assay for cyclin E overexpression, to support patient identification and enrollment of patients with cyclin E-overexpressing PROC. The Company is also expanding the trial to more than 10 clinical sites, from the nine active sites previously disclosed. This effort complements continued evaluation of tumors with CCNE1, CCNE2 or FBXW7 alterations, while an emerging clinical activity signal in PPP2R1A-mutated uterine cancers provides an additional area for evaluation as enrollment expands.

"Patients with advanced uterine and platinum-resistant ovarian cancers need additional treatment options after progression on available therapies," said Eugene Kennedy, MD, Chief Medical Advisor at Aprea. "The observed target engagement and prolonged treatment duration in a patient with a confirmed response provide a rationale to continue evaluating APR-1051 in carefully selected patients. Expanding enrollment in biologically selected populations will help us better characterize clinical activity, assess the consistency of responses and further evaluate tolerability. These data will be important for optimizing dose selection and informing subsequent development."

ACESOT-1051 Trial Design

ACESOT-1051 is a multicenter, open-label Phase 1 study evaluating oral, single-agent APR-1051 administered once daily in 28-day cycles. Part 1 includes dose escalation and backfill expansion of up to 110 patients, using accelerated titration at lower dose levels followed by a Bayesian optimal interval (BOIN) design. Backfill enrollment allows additional patients to be evaluated at dose levels that have cleared safety review. Part 2 is a dose selection optimization stage of up to 80 patients, who will be randomized 1:1 to two selected doses to determine the recommended Phase 2 dose (RP2D).

The primary objectives are to characterize safety and dose-limiting toxicities, determine the maximum tolerated or maximum administered dose, and establish the RP2D. Secondary objectives include pharmacokinetics and preliminary antitumor activity assessed using Response Evaluation Criteria in Solid Tumors (RECIST) or Prostate Cancer Working Group 3 (PCWG3) criteria, as applicable.

For more information on ACESOT-1051, refer to ClinicalTrials.gov identifier NCT06260514.

About APR-1051

APR-1051 is an investigational, orally bioavailable, selective small-molecule inhibitor of WEE1, a kinase that regulates cell cycle checkpoints and helps cancer cells respond to DNA damage. APR-1051 was designed to minimize off-target inhibition of the PLK family of kinases, with the goal of improving its therapeutic profile. Its potential differentiation remains under clinical evaluation.

(Press release, Aprea, NOV 20, 2026, View Source [SID1234675031])